Cornerstone’s Network Connection will foster communication across our network and keep members up-to-date on the latest clinical happenings relevant to community oncology as well as Cornerstone events. | | Cornerstone Specialty Network was created to provide value to community-based oncology practices to help maximize the quality of patient care. We believe in serving community oncology and educating stakeholders about the benefits of working in and caring for patients in a community setting. Through Cornerstone, we have developed a close-knit network of expert oncology physicians and direct care providers who are passionate about their work and are here to share an inside look into community oncology. Click here for the full video |  
| | ASCO Symposium occurred on July 17th, 2025, with our cochairs Dr. Edith A. Perez, Dr. Eric Schaefer, and Dr. Sujith Kalmadi highlighting key data from the 2025 ASCO Annual meeting that took place in Chicago, IL from May 30th – June 3rd, 2025. Key areas of discussion included potential novel combinations in earlier lines of treatment for HER2+ breast cancer (DESTINY-Breast09) and TNBC (ASCENT-04), the earlier use of immunotherapy in colon cancer (ATOMIC) and gastric/GEJ cancer (MATTERHORN) as well as the now approved option of immunotherapy for the treatment of patients with resectable locally advanced head and neck cancer (KEYNOTE-689). |  
| | Meet our new Vice President of Clinical Innovation and Partnerships for Clinical Affairs: Alex Cherry | |
We’re excited to welcome Alex Cherry to Cornerstone Specialty Network as our new Vice President of Clinical Innovation and Partnerships for Clinical Affairs, directly reporting to our Chief Medical Officer, Dr. Edith A. Perez.
Alex brings more than 25 years of experience in the pharmaceutical and healthcare industry, with a proven track record in commercial strategy, market access, and provider engagement—particularly in oncology, rare diseases, and hospital-based care. She has held senior leadership roles at major pharmaceutical companies, where she has led the development and execution of U.S. and global brand strategies, launched breakthrough therapies, and built cross-functional collaborations that bridged life sciences and provider networks.
At Cornerstone, Alex will leverage her deep industry expertise to drive clinical innovation and expand strategic partnerships that support community practices in delivering high-quality, value-based care. Alex’s collaborative approach and industry expertise make her a valuable addition to our team as we continue to grow and innovate. We’re thrilled to have her on board and look forward to the energy, insight, and leadership she brings to our organization.
Please join us in giving Alex a warm welcome to the team!
|  
| | |
We are pleased to share that our efforts toward advancing real-world oncology research continues to progress with our initial clinical investigation study, Prospective Observational Study on Infusion-Related Reactions with Docivyx® or Docetaxel in Participants with Solid Malignancies [Protocol CSNAVX1] sponsored by Avyxa accruing well. As of August 4, 2025, our highest two accrual sites are the Cancer Center of Kansas in Wichita with 8 patients enrolled, followed by Northwest Cancer Centers which has enrolled 6 patients. We thank Cancer Care of Kansas in Wichita and Northwest Cancer Centers for spearheading the way and all 5 practices currently participating in the study. We appreciate your dedication, responsiveness, and collaboration to move this initiative forward and support our commitment to generate impactful, practice changing insights derived directly from the community oncology setting.
We are excited to share that our second clinical investigation study Retrospective Observational Study on HR+ and HER2-Low (IHC 1+ or 2+ with ISH negative) and HER2-Ultralow (IHC0 with membrane staining) Metastatic Breast Cancer [Protocol CSNDSI01] sponsored by DSI is expected to be activated later this month. Thanks to all that have already committed to this initiative, we look forward to filling the remaining few open slots for participation!
Interested in learning more?
Please contact Milan, mmangeshkar@cornerstoneonc.com
| | | CSN COMMUNITY ONCOLOGY INSIGHTS | | | Cornerstone Specialty Network market research regarding clinical insights on Treatment Options for Breast Cancer. | | | |
FDA Updates for July 2025
On July 2, 2025, the FDA granted accelerated approval to sunvozertinib (Zegfrovy, Dizal (Jiangsu) Pharmaceutical Co., Ltd.) for adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy based on WU-KONG1B (NCT03974022), a multinational, open-label, dose randomization trial. The FDA also approved the Oncomine Dx Express Test (Life Technologies Corporation) as a companion diagnostic device to aid in detecting EGFR exon 20 insertion mutations in patients with NSCLC who may be eligible for treatment with Zegfrovy. Read More
Also on July 2, 2025, the FDA granted accelerated approval to linvoseltamab-gcpt (Lynozyfic, Regeneron Pharmaceuticals, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody evaluated in LINKER-MM1 (NCT03761108), an open-label, multi-center multi-cohort trial. Read More
| | | Save the Date - The Cornerstone Specialty Network National Summit Fall 2025 is scheduled for October 24 - 25, 2025 at the Fontainebleau Las Vegas, NV. Click below to join the waitlist. | | | |
We are looking forward to our Nurse symposium that will take place virtually on August 21st, 2025 led by Dr. Edith A. Perez, and our
co-chairs Katie Alexander, APRN-CNP, AOCNP from the Zangmeister Cancer Center and Meredith Angele, PA-C from Advocate Health Care who will be sharing the most recent practice changing data with relevant side effect management as well as the latest advancements impacting community oncology.
| | | | |
Thank You
Cornerstone would like to take this opportunity to thank our select pharma partners for their support of our programs enabling us to provide unique opportunities to connect with our network, deliver key educational programs, and ultimately benefit patient care.
| | | |
The largest and most diverse
Independent Network in Community Oncology.
| | |
Do you want to be updated on our network news and initiatives in a simple and fast way?
Follow the Cornerstone Specialty Network page on LinkedIn
Click here to follow our page!
| | | | | |
